Sugi Predict

Sugi Predict / Compounds / SCHEMBL882168

SCHEMBL882168

SCHEMBL882168

C[C@]1(OC(=O)c2ccccc2)C(OC(=O)c2ccccc2)O[C@H](COC(=O)c2ccccc2)[C@H]1OC(=O)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.49
▸ NPC1 O15118 1/20 0.42
▸ MAPT P10636 1/20 0.41
▸ POLB P06746 3/20 0.41
▸ GAA P10253 2/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ KMT2A Q03164 2/20 0.40
▸ CHRNB2 P17787 1/20 0.40
▸ CHRNA5 P30532 1/20 0.40
▸ CHRNA7 P36544 1/20 0.40
▸ CHRNA4 P43681 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ USP2 O75604 1/20 0.40
▸ SLC6A2 P23975 1/20 0.38
▸ SLC6A3 Q01959 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ CES2 O00748 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13857762 1.00 ALDH1A1 (0.49) ALDH1A1NPC1MAPTPOLBGAA
SCHEMBL13941468 1.00 ALDH1A1 (0.49) ALDH1A1NPC1MAPTPOLBGAA
SCHEMBL721635 1.00 ALDH1A1 (0.49) ALDH1A1NPC1MAPTPOLBGAA
SCHEMBL14037391 1.00 ALDH1A1 (0.49) ALDH1A1NPC1MAPTPOLBGAA
SCHEMBL14571165 1.00 ALDH1A1 (0.49) ALDH1A1NPC1MAPTPOLBGAA
SCHEMBL14853799 1.00 ALDH1A1 (0.49) ALDH1A1NPC1MAPTPOLBGAA
SCHEMBL19276651 1.00 ALDH1A1 (0.49) ALDH1A1NPC1MAPTPOLBGAA
SCHEMBL21418908 1.00 ALDH1A1 (0.49) ALDH1A1NPC1MAPTPOLBGAA
SCHEMBL21418911 1.00 ALDH1A1 (0.49) ALDH1A1NPC1MAPTPOLBGAA
SCHEMBL1287234 1.00 ALDH1A1 (0.49) ALDH1A1NPC1MAPTPOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11975016-B2 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment Atea Pharmaceuticals, Inc. (US) 2024-05-07 — — US disclosed
CN-109689672-B 2' -substituted-N for RNA viral therapy 6 -substituted purine nucleotides 阿堤亚制药公司 2023-05-30 — — CN disclosed
CN-116036114-A 2' -substituted-N for RNA viral therapy 6 -substituted purine nucleotides 阿堤亚制药公司 2023-05-02 — — CN disclosed
US-20230017958-A1 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT Atea Pharmaceuticals, Inc. (US) 2023-01-19 — — US disclosed
EP-4088725-A1 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF A VIRUS FROM THE PICORNAVIRIDAE FAMILY ATEA Pharmaceuticals, Inc. (US) 2022-11-16 — — EP disclosed
WO-2022127914-A1 NUCLEOSIDE-THIODIPHOSPHATE-HEPTOSE COMPOUNDS FOR TREATING CONDITIONS ASSOCIATED WITH ALPK1 ACTIVITY PYROTECH (BEIJING) BIOTECHNOLOGY CO., LTD. (CN) 2022-06-23 — — WO disclosed
EP-3512863-B1 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT ATEA PHARMACEUTICALS INC (US) 2021-12-08 — — EP disclosed
EP-3865136-A1 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR CORONA VIRUS TREATMENT ATEA Pharmaceuticals, Inc. (US) 2021-08-18 — — EP disclosed
US-10946033-B2 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment Atea Pharmaceuticals, Inc. (US) 2021-03-16 — — US disclosed
US-20200222442-A1 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT Atea Pharmaceuticals, Inc. (US) 2020-07-16 — — US disclosed
US-20070032448-A1 Sugar modified nucleosides as viral replication inhibitors RIBAPHARM INC. 2007-02-08 — — US disclosed
US-20070032448-A1 Sugar modified nucleosides as viral replication inhibitors RIBAPHARM INC. 2007-02-08 — — US disclosed
US-20070015905-A1 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections IDENIX PHARMACEUTICALS, INC. 2007-01-18 — — US disclosed
US-20070015905-A1 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections IDENIX PHARMACEUTICALS, INC. 2007-01-18 — — US disclosed
US-20070015905-A1 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections IDENIX PHARMACEUTICALS, INC. 2007-01-18 — — US disclosed
EP-1660511-A2 NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS Biota, Inc. (AU) 2006-05-31 — — EP disclosed
US-20050164960-A1 Methods of inhibiting orthopoxvirus replication with nucleoside compounds MERCK SHARP & DOHME CORP. 2005-07-28 — — US disclosed
WO-2005021568-A2 NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS BIOTA, INC. (AU) 2005-03-10 — — WO disclosed
EP-1476169-A1 METHODS OF INHIBITING ORTHOPOXVIRUS REPLICATION WITH NUCLEOSIDE COMPOUNDS Merck & Co., Inc. (US) 2004-11-17 — — EP disclosed
WO-2003068244-A1 METHODS OF INHIBITING ORTHOPOXVIRUS REPLICATION WITH NUCLEOSIDE COMPOUNDS MERCK & CO., INC. (US) 2003-08-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200222442-A1 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT NSUN2, ADAR, NSUN3 ALDH1A1 1861/4885NPC1 516/4885MAPT 3200/4885
US-10946033-B2 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment NSUN2, ADAR, NSUN3 ALDH1A1 1890/4885NPC1 496/4885MAPT 3129/4885
US-11975016-B2 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment NSUN2, ADAR, NSUN3 ALDH1A1 1890/4885NPC1 496/4885MAPT 3129/4885
US-20070032448-A1 Sugar modified nucleosides as viral replication inhibitors PNP, MTAP, GALE ALDH1A1 2299/4885NPC1 322/4885MAPT 3891/4885
US-20050164960-A1 Methods of inhibiting orthopoxvirus replication with nucleoside compounds ITPA, PNP, NUDT1 ALDH1A1 3163/4885NPC1 1808/4885MAPT 3958/4885
US-20070015905-A1 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections PNP, NSUN2, HAVCR2 ALDH1A1 465/4885NPC1 775/4885MAPT 2988/4885
US-20230017958-A1 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT NSUN2, ADAR, NSUN3 ALDH1A1 1861/4885NPC1 516/4885MAPT 3200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.